

Diseases of the Hemopoetic system

anemia

polycytemia

trombocytopenia

trombocytosis / trombocytemia

leukopenia

leukocytosis

aplastic anemia / bone marrow failure

myelodysplastic syndrom / MDS

myeloproliferative diseases / MPS

leukemia

Diseases of the Hemopoetic system

investigations

1. peripheral blood, PB
2. bone marrow, BM
3. organs capable of extramedullar hemopoesis
4. organs and tissues affected by the disturbances of hemopoesis

Diseases of the Hemopoetic system

anemie - PB

hematocrite

reb blood cell count

Hb

size and shape of erythrocytes / anisocytosis, poikilocytosis

anemia - BM

differential count

precursors and maturation

normoblasts / sideroblasts

biochemical and other findings

transferin, apoferritin

ANEMIA – DEFINITION

Hemoglobin (g/l)

Erythrocytes ($\times 10^{12}/l$)

Hematocrit (%)

Men

< 130–135

< 4,2

< 38 %

Women

< 115–120

< 3,8

< 35 %

Anemia – classification

- I **posthemorrhagic anemias**
 - acute
 - chronic

Anemia – classification

I posthemorrhagic anemias
acute
chronic

II of increased destruction of erythrocytes / decreased survival
hemolytic anemias
hypersplenism

Anemia – classification

- I **posthemorrhagic anemias**
 - acute
 - chronic

- II **of increased destruction of erythrocytes / decreased survival**
 - hemolytic anemias
 - hypersplenism

- III **diseases associated with a production of erythrocytes**
 - proliferation and maturation of erythroblasts**
 - impaired synthesis of DNA
 - impaired synthesis of DNA
 - unknown / unclear mechanisms
 - proliferation and differentiation of stem cells**

I. Posthemorrhagic anemias

acute

external
internal

↓
exsanguination
hypovolemic shock
anemia – restitution, Fe

sources of bleeding

- **arteries** (external x internal) aortic aneurysm rupture
stomach ulcer
tbc cavern
- **veins** (external x internal) oesophageal varices
- **organs** (liver, spleen) rupture

I. Posthemoragické anémie

acute

**externa
internal**



**exsanguination
hypovolemic shock
anemia – restitution, Fe**

chronic


**GIT
gynecologic
lungs**



**posthemorrhagic anemia
+ depletion of Fe²⁺
sideropenic anemia**

organ changes

II. Anemia of increased destruction of erythrocytes / decreased survival

- decreased survival of erythrocytes
- accumulation of catabolic substances
- increased erythropoiesis  in bone marrow
± extramedullary

II. Anemia of increased destruction of erythrocytes / decreased survival

- decreased survival of erythrocytes
- accumulation of catabolic substances
- increased erythropoiesis → in bone marrow
± extramedullary

decay of erythrocytes into particular substances

hemoglobinemia - methemoglobinemia → hemoglobinuria
methemoglobinuria
 hemosiderinuria

hem → *increased production of bilirubin* → icterus
bile sand
bile stones

iron → hemosiderosis

stroma of erythrocytes → thrombogenic

II. Anemia of increased destruction of erythrocytes / decreased survival

hemolytic anemias

two types of hemolysis

intravascular

Hb nemia – Hb uria – hyperbilirubinemia

extravascular

iron overload – hyperbilirubinemia

Hemolytic anemia

Intracorpuscular anemie

congenital

defects of membranes

hemoglobinopathy

enzymopathy

acquired (PNH)

Extracorpuscular anemia

Congenital spherocytosis

inherited as dominant trait

most frequently north Europe 1 : 5000

mutations of membrane a submembrane proteins of RBC

- ankyrin
- group 3 (band 3)
- spectrin
- protein 4.2

Congenital spherocytosis

inherited as dominant trait

most frequently north Europe 1 : 5000

mutations of membrane a submembrane proteins of RBC

- ankyrin
- group 3 (band 3)
- spectrin
- protein 4.2

clinically variable

heterozygotes

combined heterozygotes

stagnation of RBC in the spleen – phagocytosis – splenomegaly

500g -1000g

disruption of membranes – size decrease, depletion K^+

glycogen depletion

decrease of pH

Congenital spherocytosis

clinical and laboratory findings

PK anemia with a typical cytological picture

KD hyperplasia

splenomegaly

hemolytic jaundice

mild forms – almost asymptomatic

severe forms – symptomatic

Congenital spherocytosis

clinical and laboratory findings

PK anemia with a typical cytological picture

KD hyperplasia

splenomegaly

hemolytic jaundice

mild forms – almost asymptomatic

severe forms – symptomatic

during the disease – critical situations / crises:

- bone marrow failure (aplastic anemia)

(parvoviral infection – damage to normoblasts)

- hemolytic crisis

(splenic activation, e.g. at IM)

cholelithiasis and its complication

Sickle cell anemia

Thalassemia

adults

| | | |
|------|-----------------------|-----|
| HbA | - $\alpha_2\beta_2$ | 96% |
| HbA2 | - $\alpha_2\delta_2$ | 3% |
| HbF | - $\alpha_2\lambda_2$ | 1% |

Thalasemie

beta – defect of β chain

gen na chromosome 16

point mutations

homozygotes x heterozygotes

Thalassemia

alpha – defects of α chain

2 genes in a tandem - chromosome 11

mutations - deletions

homozygotes x heterozygotes

Paroxysmal nocturnal hemoglobinuria

clonal proliferation of a stem cell with a mutated gene:

Phosphatidyl Inositol Glykan Ancor biosynthesis class A (**PIGA**)

protein is necessary for binding – membraneous proteins

covalent binded proteins to cell membranes

GPI (*glykosylphosphatidylinositol*) – fuction of a membrane ancor

Xlinked - Xp22.1 (*PIGA lyonized*) one alele mutation suffices

KD clonal expansion of progenitor cells of all BM hemopoetic cells
 persisting normal and pathological hemopoesis

sometimes develops after a bone marrow failure, esp. autoimmune induced

Paroxysmal nocturnal hemoglobinuria

- impaired function of
3 proteins preventing complement activation → prevention of hemolysis
 - CD55 (DAF)
 - binding protein C8
 - CD59 (convertase C3 inhibitor)

RBC undergo lysis after an attack of C5b-9 (attack membraneous complex)

Paroxysmal nocturnal hemoglobinuria

- impaired function of
3 proteins preventing complement activation → prevention of hemolysis
 - CD55 (DAF)
 - binding protein C8
 - CD59 (convertase C3 inhibitor)

RBC undergo lysis after an attack of C5b-9 (attack membraneous complex)

- **chronic hemolysis, PNH in only about 25%**
- **anemia usually mild to moderate**
- **there is iron depletion - hemosiderinuria**

- **risk factors**
 - venous thrombosis ↑↑ – peripheral, hepatic, portal, CNS in up to 40%
 - transformation in AML or MDS 5 to 10 %

Paroxysmal nocturnal hemoglobinuria

- impaired function of
3 proteins preventing complement activation → prevention of hemolysis
 - CD55 (DAF)
 - binding protein C8
 - CD59 (convertase C3 inhibitor)

RBC undergo lysis after an attack of C5b-9 (attack membrane complex)

- chronic hemolysis, PNH in only about 25%
- anemia usually mild to moderate
- there is iron depletion - hemosiderinuria
- risk factors
 - venous thrombosis ↑↑ – peripheral, hepatic, portal, CNS in up to 40%
 - transformation in AML or MDS 5 to 10 %

therapy

monocl. anti C5 (Eculizumab) – increased risk of meningococcal sepsis
immunosuppression, bone marrow transplantation

Hemolytic anemias

Intracorpuscular

congenital

membrane defects

hemoglobinopathy

enzymopathy

acquired (PNH)

Extracorpuscular

immuno-hemolytic

warm antibodies

cold agglutinins

cold hemolysins

traumatization of erythrocytes

other

Hemolytic anemias

Extracorpascular immuno-hemolytic

warm antibodies – active at 37°C IgG

primary

secondary

- drug induced – penicillin, cefalosporin

- SLE

- lymphomas e.g. CLL / SLL

cold agglutinins – active below 37°C IgM

- acute at IM, mycoplasma pneumoniae, CMV, HIV and other

- chronic

primary

lymphomas

cold hemolysins – active below 37°C IgG

rare, children – viral infections

traumatization of erythrocytes

Anemia – classification

I posthemorrhagic anemias

acute

chronic

II of increased destruction of erythrocytes / decreased survival

hemolytic anemias

hypersplenism

Anemia – classification

- I posthemorrhagic anemias
 - acute
 - chronic

- II of increased destruction of erythrocytes / decreased survival
 - hemolytic anemias
 - hypersplenism

- III **diseases associated with a production of erythrocytes**
 - proliferation and maturation of erythroblasts**
 - impaired synthesis of DNA
 - impaired synthesis of DNA
 - unknown / unclear mechanisms
 - proliferation and differentiation of stem cells**

III. Anemia – impaired synthesis of DNA

megaloblastic anemias = lack of folic acid (B9) / vitamin B12

dysbalance: ↓ intake x ↑ demands

III. Anemia – impaired synthesis of DNA

megaloblastic anemias = lack of folic acid (B9) / vitamin B12

dysbalance: ↓ intake x ↑ demands

B12 – pernicious anemia (*Addison-Biermer*)

cause – chronic atrophic gastritis, type A
decrease or absence of the intrinsic factor →
depletion of B12

| | | |
|-------------------|---------------------|---|
| findings – | GIT | gastritis, mucosal atrophy |
| | BM | hyperplasia, megaloblasts, asynchrony, ineffective hemopoiesis |
| | PB | anemia, leukopenia, thrombocytopenia |
| | CNS | funicular myelopathy |
| | other organs | heart, liver, kidneys, brain |

III. Anemia – impaired hemoglobin synthesis

sideropenic anemia (iron deficiency anemia, microcytic)

imbalance: ↓ intake × ↑ demands × iron incorporation defects

III. Anemia – impaired synthesis of hemoglobin / iron deficiency anemia

iron metabolism

intake

bound in hem (25%)

free iron (1 - 2%)

transport

storage

compartments

functional
stores

losses

1 – 1,5 mg / day

anemia develops

- food intake

↓

- demands

↑

- iron incorporation

primary

– sideroachrestic

secondary

– lead poisoning, BM carcinosis

Bone marrow failure / pathology of proliferation and differentiation of stem cells

acquired idiopathic

defects of stem cells
immune related ?

**chemically induced
dose related**

alkylating drugs
antimetabolites (VCR)
chloramfenicol
benzene

idiosyncratic

fenylbutazone
chlorpromazine
chloramfenikol
streptomycine

**physical
virus induced**

HB, CMV, EBV, V-Z

inherited

Bone marrow failure – carcinosis of bone marrow

Polycytemia - classification

relative

decrease volume of plasma (hemoconcentration)

absolute

primary – polycythemia vera (MPS)

secondary

– **appropriate**

high altitude

cardiac diseases

lung diseases

– **inappropriate**

neoplasms producing

erythropoetin

Thrombocytopenia - classification

decreased production of platelets

generalized BM diseases

selective

infective megakaryopoiesis

infiltrative

BM failure

drugs

infections (rubeolla)

inherited (W.A. syndrome)

acquired (megalobl. anemia)

decreased lifespan of platelets

consumptive

destruction

DIC, KM syndrome

auto ab (ITP, SLE)

iso agglutinins

drugs (heparine)

infections (EBV, HIV)

platelet sequestration

hypersplenism